A number of monoclonal antibodies targeting PD-1 or PD-L1 have demonstrated beneficial treatments against several tumour types, including melanoma29,30, hepatic carcinoma31, non-small cell lung cancer32, and Hodgkin’s lymphoma33. This evidence concerns the gene PDCD1 and neoplasm.